Resistance to Chloroquine by \u3ci\u3ePlasmodium vivax\u3c/i\u3e at Alor in the Lesser Sundas Archipelago in Eastern Indonesia by Sutanto, Inge et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2009
Resistance to Chloroquine by Plasmodium vivax at
Alor in the Lesser Sundas Archipelago in Eastern
Indonesia
Inge Sutanto
Department of Parasitology, Faculty of Medicine, University of Indonesia
Sri Suprijanto
Communicable Disease Control, Ministry Health of Indonesia, Jalan Percetakan Negara No 29, Jakarta
Department of Parasitology, Faculty of Medicine, University of Andalas, Jalan Perintis Kemerdekaan
Paul Manoempil
Timor Leste Asistensia Integrado Saude (TAIS), Delegasi Saude (USAID), rua Bairo Formoza, Dili, Timor Leste
J. Kevin Baird
ALERTAsia Foundation, jkevinbaird@yahoo.com
Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Sutanto, Inge; Suprijanto, Sri; Department of Parasitology, Faculty of Medicine, University of Andalas, Jalan Perintis Kemerdekaan;
Manoempil, Paul; and Baird, J. Kevin, "Resistance to Chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in
Eastern Indonesia" (2009). Public Health Resources. 397.
http://digitalcommons.unl.edu/publichealthresources/397
Am. J. Trop. Med. Hyg., 81(2), 2009, pp. 338–342
Copyright © 2009 by The American Society of Tropical Medicine and Hygiene
338
* Address correspondence to Inge Sutanto, Department of Parasitology, 
Faculty of Medicine, University of Indonesia, Jalan Salemba Raya No 6, 
Jakarta 10430, Indonesia. E-mail:  sutanto.inge@yahoo.com 
 Resistance to Chloroquine by  Plasmodium vivax at Alor in the Lesser Sundas 
Archipelago in Eastern Indonesia 
 Inge  Sutanto , *  Sri  Suprijanto ,  Nurhayati ,  Paul  Manoempil , and  J. Kevin  Baird 
 Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Malaria Subdirectorate, CDC, Ministry of Health, 
Jakarta, Indonesia; Department of Parasitology, Faculty of Medicine, University of Andalas, Padang, Indonesia; District Health Office, Kalabahi, 
Alor District, East Nusa Tenggara, Indonesia, Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Centre for Tropical Medicine Nuffield 
Department of Clinical Medicine, Oxford University, Oxford, United Kingdom 
 Abstract.  The therapeutic response to standard chloroquine therapy against  Plasmodium vivax was evaluated in 36 
subjects living at Alor in the Lesser Sundas Archipelago of eastern Indonesia. Chloroquine level were measured on 32 
individuals, and showed evidence of adequate absorption of standard chloroquine therapy. Three subjects failed treat-
ment by Day 2 or 3, with evidence of rising asexual parasitemia, and two others had stable parasitemia to Day 7. Ten more 
subjects had recurrent parasitemia by Day 14, two by Day 21, and another one by Day 28. Three subjects had recurrent 
parasitemia on Days 14 and 28, but with chloroquine < 100 ng/mL. Eleven subjects cleared parasitemia by Day 3 and had 
no recurrences up to Day 28. In summary, 28-day cumulative incidence of confirmed resistance to chloroquine was 56% 
of infections evaluated. Chloroquine should not be considered adequate for treatment of acute vivax malaria acquired in 
this region. 
 INTRODUCTION 
 Plasmodium vivax infects 130–435 million people each year, 
causing a debilitating and potentially fatal course of febrile dis-
ease. 1,2 Despite evidence of emerging resistance to chloroquine 
(CQ), the 60-year-old frontline therapy against this infection, 
few alternative therapies have been adequately evaluated and 
few studies document the extent of the problem. 3–6 
 Relapse by  P. vivax , emergence of latent liver stages into the 
blood, confounds the estimation of drug efficacy. Recurrent 
parasitemia after therapy may be the product of recrudes-
cence of drug-resistant blood stages, reinfection of the subject 
by biting anopheline mosquitoes, or relapse. Molecular mark-
ers of strain identity, so useful in sorting out recrudescence and 
reinfection in  P. falciparum , fail with  P. vivax on the weight of 
ambiguities imposed by relapse. The  in vivo test for resistance 
to CQ hinges on levels of CQ and its major metabolite, deseth-
ylchloroquine (DCQ), in blood. 7 Asexual parasites appearing 
with effective drug levels may be classified as resistant whether 
representing a recrudescence, reinfection, or relapse. 7 The dif-
ficulty imposed by drug measurements limits the availability 
of reliable information on resistance in  P. vivax . Nonetheless, 
infections that do not recur after therapy may be unambigu-
ously classified as sensitive without the aid of drug levels in 
blood, as has been done in Thailand. 8,9 
 Surveys of resistance to CQ by  P. vivax in Indonesia showed 
high risk of failure at Papua in the east, intermediate risk at 
Kalimantan and Sulawesi in the center, and low risk at Nias, 
Sumatra in the west. 7,10–18 This range of verified resistance in 
Indonesia required determination of drug levels in blood and 
has limited the availability of reliable data from this coun-
try. No surveys have yet been reported from anywhere in the 
Lesser Sundas Archipelago stretching across the southern 
fringe from central to eastern Indonesia. This report describes 
a survey of CQ resistance in  P. vivax from Alor Island near the 
eastern end of the Lesser Sundas Archipelago. 
 MATERIALS AND METHODS 
 Recruitment.  Between November 2001 and March 2002, we 
conducted passive surveillance for malaria among people with 
fever, or a history of fever within 24 hours, and seeking medical 
attention at a local primary health care facility. Patients with 
slide-proven  P. falciparum were enrolled in a randomized 
evaluation of CQ versus sulfadoxine-pyrimethamine. 19 Patients 
with  P. vivax mono-infection diagnosed by Giemsa-stained 
blood films were screened for enrollment in this study. Ethical 
clearance for this study was obtained from the Committee of 
Medical Research Ethics of the Faculty of Medicine, University 
of Indonesia, Jakarta, Indonesia. All adult subjects and parents 
of child participants signed informed consent for this study 
individually. Inclusion criteria for enrolled subjects were 
being 1 year or older,  P. vivax mono-infection ≥ 1,000 asexual 
parasites/μL, axillary temperature < 39.5°C, ability to come 
for follow-up visits, and willingness to sign informed consent. 
Patients were excluded if they showed signs of severe disease, 
severe malnutrition, pregnancy (by urine test) or evidence of 
another febrile illness. Recent consumption of antimalarials 
was not a basis for exclusion. 
 Parasitology.  Blood smears (thick and thin) were stained 
with 3% Giemsa for 30 minutes and examined twice: first in the 
field and second by an independent reader in our laboratory 
in Jakarta. Study endpoints were based on findings of the 
second reader. Blood films were examined by light micros-
copy using ×1,000 oil immersion magnification. The number 
of parasites per 200 white blood cells (WBCs) was multiplied 
by 40 to estimate the number of parasites per microliter blood 
(assumes 8,000 WBC/μL). 
 Treatment and follow-up.  Subjects were treated with un-
coated CQ tablets (chloroquine phosphate, Resochin; PT Bayer, 
Cibubur, Indonesia) over 3 days (25 mg base/kg: 10 mg/kg on 
Days 0 and 1, and 5 mg/kg on Day 2). All drug administration 
was supervised in the health center; subjects who vomited in 
the first 30 minutes were given another dose. Paracetamol was 
provided to subjects with an axillary temperature ≥ 38.5°C. 
 Study subjects were followed for 28 days. We asked they 
return to the health center on Days 1, 2, 3, 7, 14, 21, and 28. 
At each visit, an axillary temperature was taken. In addition, a 
blood sample was collected by finger prick, with several drops 
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placed onto microscope slides. A heparinized, graduated capil-
lary tube was used to place 50 μL whole blood onto Whatman 
filter paper no 1. Subjects not clearing their parasitemia or 
developing recurrent parasitemia during the follow-up period 
were given unsupervised oral quinine for 7 days (3 × 10 mg/kg, 
maximum 2,000 mg) plus primaquine for 14 days (0.25 mg/kg/
day). Subjects with successful treatment (no recurrence within 
28 days) were given 14 days of primaquine at the end of the 
study to eliminate relapse. 
 Treatment outcomes.  Subjects were dropped from the 
study on treatment failure, loss to follow-up, or reaching Day 
28 without a recurrent parasitemia. Subjects were classified 
as direct treatment failures if they showed parasitemia on 
Day 3 ≥ 25% of the parasitemia on Day 0. Subjects were 
classified as early treatment failures if they showed any level 
of parasitemia persisting to Day 4. We classified subjects 
having recurrent parasitemia at any level between Days 5 
and 28 as recurrence failures. We classified treatment failures 
as resistant to CQ when persistent or recurrent parasitemia 
appeared with > 100 ng/mL CQ + DCQ, the minimal effective 
concentration against CQ-sensitive  P. vivax . 7 Subjects clearing 
parasitemia by Day 4 and not having a recurrence by Day 28 
were classified as having CQ-sensitive vivax malaria. 
 Subjects were classified as lost to follow-up if they failed 
to show up during the follow-up period. Subjects were classi-
fied as withdrawn from the study for protocol violations, i.e., 
inadequate compliance to therapy, inter-current parasitemia 
with  P. falciparum during follow-up, recurrent  P. vivax para-
sitemia with < 100 ng/mL CQ + DCQ, or onset of another dis-
ease requiring additional therapy. 
 Whole blood CQ + DCQ.  Whole blood CQ concentrations 
were quantified on Day 0 (before drug administration), Day 3 
(1 day after third dose), on day of recurrent parasitemia, or on 
Day 28 of the test. CQ and its major metabolite, DCQ, were 
extracted from fixed volumes of dried whole blood on filter paper 
and determined by high-performance liquid chromatography 
(HPLC) according to the method of Patchen and others. 20 Whole 
blood CQ level was calculated as the sum of CQ + DCQ. 7 
 Statistics.  We used the life table method of estimating 
cumulative incidence of therapeutic failure for the 36 enrolled 
individuals as described elsewhere and per-protocol analysis 
for the 32 subjects. 7 Data were analyzed using SPSS version 
12.0 (SPSS, Chicago, IL) software. Discrete data were analyzed 
using either a χ 2 , with or without Yates correction, or Fisher 
exact test. Continuous data were compared using Student’s 
 t test or Mann-Whitney test for analysis of non-parametric 
data. Pearson correlations were calculated to justify the 
relationships between two quantitative variables. The level of 
statistical significance was set at  P < 0.05. 
 RESULTS 
 Passive case detection.  A total of 292 patients of 796 screened 
were malaria positive. Among positives, 66% (192/292) were 
 P. falciparum , 30% (87/292) were  P. vivax, and 4.5% (13/292) 
were mixed infection of  P. falciparum and  P. vivax. Thirty-
six of 87 (41.4%)  P. vivax cases met inclusion criteria. The 
51 exclusions were from age (2), pregnancy (5), no asexual 
parasitemia (13), inadequate asexual parasitemia (27), or 
declining informed consent (4). 
 Subjects.  The 36 subjects included 21 males and 15 females 
between 1 and 40 years of age (median, 7.5 years; interquartile 
range, 3.6–11.8 years). Ten subjects had evidence of fever 
(≥ 37.5°C) at enrollment, whereas all others complained of 
fever within the last 24 hours. Before drug administration, 
geometric mean of asexual forms was 3,806.7 (range, 1,000–
18,280/μL, 95% CI: 3829.3–6326.2/μL), whereas the geometric 
mean of sexual stages of 20 gametocyte-positive subjects was 
83.8/μL (range, 40–3,200/μL, 95% CI: −78.5 to 578.5/μL). 
 The 32 enrolled subjects were examined for whole blood 
CQ level. Twenty-four of 32 subjects evaluated had detect-
able CQ in blood before treatment (median, 55 ng/mL; inter-
quartile range, 10–100 ng/mL), and 17 (53%) had > 100 ng/
mL. There was no association between CQ in blood of 32 
patients on Day 0 and treatment outcomes (Fisher exact test, 
 P = 0.273). During follow-up, seven subjects were withdrawn 
from the study: one with inter-current  P. falciparum para-
sitemia on Day 7; one subject left the area on Day 14; three 
subjects had recurrent  P. vivax parasitemia on Days 14 and 
28, but with CQ < 100 ng/mL; and two dropped out on Days 7 
and 14 without citing reasons. 
 Fever and parasite clearance times.  Seven of 10 febrile sub-
jects were afebrile within 24 hours, one subject cleared fever 
within 48 hours, and two subjects became afebrile within 72 
hours.   The median fever clearance time was 1 day (interquartile 
range, 1–2 days). 
 Thirty subjects were evaluated for parasite clearance. The 
five subjects failing to clear parasitemia and one showing 
mixed infection on Day 7 were excluded from this analysis. The 
median parasite clearance time was 3 days (interquartile range, 
2–3 days), where 40% (12/30) were free of parasites on Day 2, 
36.7% (11/30) cleared on Day 3, and 23.3% (7/30) cleared on 
Day 7. We detected no significant correlation between para-
site clearance time and geometric mean of parasite density at 
enrollment (Pearson correlation,  r = 0.319,  P = 0.104). We also 
did not detect a significant difference in geometric mean para-
site density at enrollment between treatment failures (mean 
rank, 17.64) and successes (mean rank, 14.32; Mann-Whitney, 
 P = 0.341). 
 CQ + DCQ post-therapy.  We considered CQ + DCQ levels 
> 500 ng/mL on Day 3 to be consistent with normal adherence 
to and absorption of CQ therapy. Only one subject of 32 failed 
this with 450 ng/mL. Nonetheless, that subject did not become 
parasitemic again and was thus included in our analysis as a 
fully sensitive infection. The Day 3 median CQ + DCQ levels 
for the 32 subjects were 725 ng/mL (interquartile range, 
625–843.8 ng/mL). We found no correlation between level of 
CQ on Day 0 and Day 3 (Pearson correlation,  r = 0.223,  P = 
0.219). No association appeared between level of CQ on Day 
3 and treatment success or failure (failed groups mean rank, 
16.9; successful groups mean rank, 11.9; Mann-Whitney test, 
 P = 0.126). Evidence of recent CQ consumption had no 
apparent impact on either peak drug levels after standard 
therapy or on therapeutic outcomes. 
 Therapeutic failures.  During the first 3 days of follow-up, 
three subjects had stable parasite counts and were classified as 
direct treatment failures (8.3%). One subject showed higher 
parasite counts on Day 2 (Day 0 = 5,240/μL, Day 2 = 6,320/μL), 
and the other two had essentially equal parasite counts (1,120/
μL versus 1,040/μL and 8,960/μL versus 11,000/μL on Days 0 
and 3, respectively;  Tables 1 and  2 ). The CQ + DCQ levels on 
these three subjects were 800, 625, and 800 ng/mL, respectively, 
and we thus considered these infections as evidence of high-
grade resistance to CQ. 
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 Another two subjects had significantly decreased counts on 
Days 2 and 3 compared with Day 0, but neither was eliminated 
by Day 7 (9,240/μL versus 40/μL and 9,440/μL versus 80/μL on 
Days 0 and 7, respectively). These parasitemias occurred with 
320 and 275 ng/mL CQ + DCQ and were thus classified as 
early treatment failures ( Table 2 ). 
 Thirteen subjects cleared asexual parasitemias that later 
recurred. Ten of these appeared by Day 14, all of which had CQ 
+ DCQ levels > 100 ng/mL. One subject recurred on Day 14 
with no detectable CQ + DCQ in blood despite having had 
normal levels at Day 3 (625 ng/mL). Further recurrent par-
asitemia appeared on Day 21 (2 subjects) and on Day 28 
(3 subjects). Measurement of CQ + DCQ levels confirmed 
resistance of two and one persons on Days 21 and 28, respec-
tively. The three subjects with recurrent parasitemia with < 100 
ng/mL CQ + DCQ on Days 14 and 28 were treated as with-
drawn from the analysis ( Tables 1 and  2 ). 
 In summary, 18 subjects of 36 successfully enrolled (50%) 
had infections showing evidence of resistance to CQ. Only 29 
subjects reached study endpoints without being withdrawn, 
and the 18 failures constituted 62% of that total. We used the 
life table method to more accurately estimate risk of failure 
over the 28-day period of observation, taking into account the 
person-time at risk of the seven subjects ultimately withdrawn. 
This figure was 55.7% ( Table 1 ). The 7-day risk of direct or 
early treatment failure in this population was 13.9%, or 28% 
of treatment failures. 
 DISCUSSION 
 One half of the 36 infections by  P. vivax evaluated at Alor 
in the eastern Lesser Sundas Archipelago showed evidence of 
resistance to CQ. The estimated cumulative incidence of resis-
tant case was 56%. This degree of resistance accords with that 
described at Timika along the southern coast of Papua, the 
site nearest Alor having available data ( Figure 1 ). 6,15 This find-
ing suggests resistance to CQ may dominate vivax malaria in 
the eastern Lesser Sundas Archipelago, perhaps as much as in 
Papua. Five of the subjects evaluated in this study had direct 
(three individuals) and early (two subjects) treatment failures 
with rising or persisting parasitemia despite normal absorp-
tion of CQ. These outcomes raise the specter of very high-
grade resistance against this infection, as is known in Papua. 
Our limited findings suggest vivax malaria acquired in this 
region should not be treated with CQ. 
 Some work in the region has shown effective alternative ther-
apies for CQ-resistant vivax malaria. Combining high doses of 
primaquine with CQ proved substantially superior to CQ alone 
against  P. vivax (30% versus 85% efficacy). 3 Maguire and oth-
ers 5 observed similar efficacy of CQ combined with standard 
primaquine therapy against vivax malaria. Mefloquine com-
bined with primaquine proved almost completely efficacious 
in the same study. 5 Combining standard CQ and 7 days of 
200 mg daily doxycycline was less effective (71%) than CQ 
plus primaquine. 4 A fixed combination of atovaquone-progua-
nil (Malarone) proved effective against vivax malaria in a lim-
ited number of subjects in northern Papua. 21 Several recent 
studies in southern Papua showed high levels of resistance 
(65%) to CQ in  P. vivax and that a fixed combination of dihy-
droartemisinin-piperaquine provided superior efficacy against 
sexual and asexual forms of those parasites compared with 
artemether-lumefantrine or artesunate-amodiaquine. 6,22 
 The policy of the Ministry of Health of Indonesia today rec-
ommends CQ as first-line therapy for vivax malaria across 
all of Indonesia. However, an exception has been made for 
the region of Timika in southern Papua where the above-
cited studies were conducted. There the Ministry of Health 
recommends use of dihydroartemisinin combined with pip-
eraquine, presumably on the weight of evidence from those 
 Table 1 
 Cumulative incidence of resistant cases 
Day  N I W IR CIR
0 36 0 0 0 0
2 36 1 0 0.0278 0.0278
3 35 2 0 0.0571 0.0833
7 33 2 2 0.0606 0.1388
14 29 10 3 0.3636 0.4520
21 16 2 0 0.125 0.5205
28 14 1 2 0.0769 0.5574
 Day = day of the test;  N = number of subjects remaining at risk; I = incidence of resistant 
cases; W = withdrawals caused by intercurrent parasitemia by the other species or lost to 
follow up or recurrent  P. vivax parasitemia with < 100 ng/mL CQ + DCQ; IR, interval risk 
i[ N − (w/2)] −1 ; CIR n = cumulative incidence of resistant case = 1 − (1 − IR n × 1 − CIF n−1 ), 
where n is day of test and n − 1 is the prior interval (e.g., for calculating CIR Day 14, use IR 
Day 14 and CIR Day 7). 
 Table 2 
 Outcomes of  in vivo drug study 
Summary statistic
Total subjects evaluated 36
Direct treatment failure 3 (8.3%)
Early treatment failure 2 (5.6%)
Recurrent treatment failure 13 (36.1%)
Fully CQ sensitive 11 (30.6%)
Withdrawn 7 (19.4%)
 Figure 1 .  Sites in Indonesia having > 50% risk of therapeutic failure of standard CQ therapy for vivax malaria: current study site at Alor (star), 
and (from left to right) sites in Papua at Nabire, Timika, Armopa, and Arso. This figure appears in color at  www.ajtmh.org . 
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studies. However, similar policy provision has yet to be made 
on the weight of evidence of an equal or greater resistance 
problem in vivax malaria along the northern coast of Papua 
from Nabire to Jayapura. 3–5,11–14 Moreover, other areas of 
Indonesia have significant resistance problems not yet so well 
documented. For example, we measured a CQ failure rate of 
58% in vivax malaria occurring in southern Sumatra (Sutanto 
and others, unpublished data). These findings from Alor further 
emphasize that substantial evidence shows a severe resistance 
problem extending far beyond Papua. Treatment recommen-
dations by the Indonesian Ministry of Health should consider 
these data in weighing the decision to retain CQ as first-line 
therapy for vivax malaria. 
 In summary, a single survey of 36 subjects infected by 
 P. vivax suggests a serious problem with CQ therapy against 
this parasite in the Lesser Sundas Archipelago. This work, 
along with studies from northern and southern Papua, sug-
gest a broad region in eastern Indonesia where CQ-resistant 
strains of  P. vivax predominate over CQ-sensitive strains. 
Clinical studies showed the safety and efficacy of dihydroar-
temisinin combined with piperaquine against CQ-resistant  P. 
vivax in eastern Indonesia, and this fixed combination should 
be considered for adoption as first-line therapy for malaria 
throughout Indonesia. 
 Received May 29, 2008.  Accepted for publication April 15, 2009. 
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